TABLE 4.

Anticancer drugs included in this systematic review, categorised by therapeutic class.

Chemotherapy		Targeted Therapy			Immunotherapy
Anthracycline	Platinum Compound	Anaplastic Lymphoma Kinase (ALK) Inhibitor	Angiogenesis Inhibitor	Epidermal Growth Factor Receptor (EGFR) Inhibitor	Programmed cell death protein 1/death ligand 1 (PD-1/PDL-1) Inhibitor	Epidermal Growth Factor Receptor (EGFR) Inhibitor
Amrubicin (L01DB10)	Carboplatin (L01XA02)	Alectinib (L01ED03)	Nintedanib (L01EX09)	Erlotinib (L01EB02)	Avelumab (L01FF04)	Cetuximab (L01FE01)
Epirubicin (L01DB03)	Cisplatin (L01XA01)	Brigatinib (L01ED04)	Sorafenib (L01EX02)	Gefitinib (L01EB01)		Necitumumab (L01FE03)
		Crizotinib (L01ED01)	Sunitinib (L01EX01)	Osimertinib (L01EB04)		Panitumumab (L01FE02)

Alkylating Agent	Anti-metabolite Agent	Cyclooxygenase-2 (COX-2) Inhibitor	Mitogen-activated protein kinase (MEK) inhibitors	Poly (ADP-ribose) polymerase (PARP) inhibitor	Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor	mRNA-based
Ifosfamide (L01AA06)	Gemcitabine (L01BC05 - Pyrimidine analogues)	Celecoxib (L01XX33)	Selumetinib (L01EE04)	Veliparib (L01XK05)	Trastuzumab (L01FD01)	CV9201
	Pemetrexed (L01BA04 – folic acid analogues)		GSK1120212/ Trametinib (L01EE01)

Plant Alkaloid		Vascular Endothelial Growth Factor (VEGFR) Inhibitor
Docetaxel (L01CD02)		Bevacizumab (L01FG01)
Etoposide (L01CB01)
Paclitaxel (L01CD01)
Vinorelbine (L01CA04)